PACB - הכנסה תפעולית לפני ניכוי פחת pacb.com

Pacific Biosciences (PACB) minimizes single-product risks through its specialization in DNA sequencing equipment, given the critical importance of these systems for science. The company's absolute operating profit in monetary terms illustrates this trend, where the level of 0.00 represents the current value. Revenues are based on long-term customer lock-in via proprietary cartridges, while profits are generated by B2B deliveries of HiFi systems and the regular sale of reagents to biopharmaceutical behemoths.

This indicator is indispensable for asset stress testing, as it allows for an assessment of the business's actual ability to generate cash flow before taxes and debt obligations. By analyzing the current EBITDA of Pacific Biosciences (PACB), an investor can see the monetization efficiency of the Revio and Onso systems, where a steadily rising curve confirms high margins on equipment sales and consistent demand for specialized genomic analysis reagents.